Fidelity Select Biotechnology holds a quantitatively derived Silver Morningstar Medalist Rating. The rating reflects that it has scored well on factors Morningstar research associates with future outperformance relative to category peers.
Fidelity Select Biotechnology Portfolio FBIOX
- NAV / 1-Day Return 28.24 / −0.25 %
- Total Assets 6.0B
-
Adj. Expense Ratio
0.620%
- Expense Ratio 0.620%
- Distribution Fee Level Low
- Share Class Type No Load
- Category Health
- Investment Style Mid Growth
- Min. Initial Investment 0
- Status Open
- TTM Yield 1.47%
- Turnover 45%
USD | NAV as of Oct 03, 2026 | 1-Day Return as of Oct 03, 2026, 12:11 AM GMT+0
Morningstar’s Analysis FBIOX
Will FBIOX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 42.7
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
AbbVie Inc | 11.04 | 640M | Healthcare |
Krystal Biotech Inc | 10.61 | 615M | Healthcare |
Amgen Inc | 6.79 | 393M | Healthcare |
Revolution Medicines Inc Ordinary Shares | 2.31 | 134M | Healthcare |
Praxis Precision Medicines Inc Ordinary Shares | 2.19 | 127M | Healthcare |
Insmed Inc | 2.11 | 122M | Healthcare |
argenx SE ADR | 2.08 | 121M | Healthcare |
Ascendis Pharma AS | 2.02 | 117M | Healthcare |
Alnylam Pharmaceuticals Inc | 1.81 | 105M | Healthcare |
Jazz Pharmaceuticals PLC | 1.75 | 102M | Healthcare |